RESTEM Group is a clinical-stage biotechnology company with a groundbreaking adult stem cell therapy platform with one Phase 2/3I and one Phase 1 clinical trials currently underway, and an additional one Phase 2 trial set to commence. We have successfully completed three Phase 1 clinical trials. Through Restem-L, our proprietary Umbilical Lining Modified Progenitor Cells (UMPCs) platform, RESTEM’s therapies have the potential to become best-in- class treatments for the underserved autoimmune community. RESTEM is strategically positioned to bring this innovative treatment to market.

RESTEM’s activated natural killer (aNK) cells program is designed to combat age-related diseases by targeting and reversing cellular senescence. Cellular senescence is a hallmark of aging and involves the arrest of cell division, which contributes to chronic inflammation, tissue dysfunction, and the progression of various age-associated disorders.